A83-01 - CAS 909910-43-6
Not Intended for Therapeutic Use. For research use only.
Category:
Inhibitor
Product Name:
A83-01
Catalog Number:
B0084-155117
CAS Number:
909910-43-6
COA:
Inquire
MSDS:
Inquire
Targets:
TGF-β Receptor
Catalog Number Size Price Stock Quantity
B0084-155117 50 mg $198 In stock
Bulk Inquiry
Chemical Structure
CAS 909910-43-6 A83-01

Related TGF-β Receptor Products


CAS 446859-33-2 Repsox

Repsox
(CAS: 446859-33-2)

Repsox is an inhibitor of the TGF-β type 1 activin like kinase receptor ALK5. At 25 μM, it can be used to induce stem cell pluripotency by replacing the reprogr...

CAS 700874-72-2 Galunisertib

Galunisertib
(CAS: 700874-72-2)

Galunisertib, also known as LY2157299, is a novel selective small molecule transforming growth factor beta receptor (TGF-βR) kinase inhibitor.LY2157299 inhibite...

CAS 452342-67-5 GW788388

GW788388
(CAS: 452342-67-5)

CAS 356559-20-1 SB525334

SB525334
(CAS: 356559-20-1)

CAS 607737-87-1 A-77-01

A-77-01
(CAS: 607737-87-1)

A-77-01 is an inhibitor of TGF-β type I receptor superfamily activin-like kinase ALK5( IC50 =25nM).

CAS 396129-53-6 LY364947

LY364947
(CAS: 396129-53-6)

LY364947 is a selective inhibitor of TGF-β type-I receptor with potential anticancer activity. LY364947 inhibits TGF-β-dependent luciferase production in mink l...

CAS 909910-43-6 A83-01

A83-01
(CAS: 909910-43-6)

ITD-1
(CAS: 1099644-42-4)

ITD-1 is an effective and highly selective TGF-β signaling inhibitor which could promote cardiomyocyte differentiation through degradation of the TGFBR2 so that...

CAS 627536-09-8 SD-208

SD-208
(CAS: 627536-09-8)

SD-208 is a selective TGF-βRI (ALK5) inhibitor with IC50 of 48 nM, >100-fold selectivity over TGF-βRII.

CAS 1352608-82-2 EW-7197

EW-7197
(CAS: 1352608-82-2)

EW-7197 is a potent ALK5 inhibitor. EW-7197 showed potent in vivo anti-metastatic activity, indicating its potential for use as an anti-cancer therapy. EW-7197...

Reference Reading


1.Topical application of ALK5 inhibitor A-83-01 reduces burn wound contraction in rats by suppressing myofibroblast population.
Sun X1, Kim YH, Phan TN, Yang BS. Biosci Biotechnol Biochem. 2014;78(11):1805-12. doi: 10.1080/09168451.2014.932666. Epub 2014 Jul 10.
Burn scar contracture that follows the healing of deep dermal burns causes severe deformation and functional impairment. However, its current therapeutic interventions are limited with unsatisfactory outcomes. When we treated deep second-degree burns in rat skin with activin-like kinase 5 (ALK5) inhibitor A-83-01, it reduced wound contraction and enhanced the area of re-epithelialization so that the overall time for wound closing was not altered. In addition, it reduced myofibroblast population in the dermis of burn scar with a diminished deposition of its biomarker proteins such as α-SMA and collagen. Treatment of rat dermal fibroblast with A-83-01 inhibited transforming growth factor-β1 (TGF-β1)-dependent induction of α-SMA and collagen type I. Taken together, these results suggest that topical application of ALK5 inhibitor A-83-01 could be effective in preventing the contraction of burn wound without delaying the wound closure by virtue of its inhibitory activity against the TGF-β-induced increase of myofibroblast population.